Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Sirius XM Holdings Inc (SIRI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Sirius XM Holdings Inc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $299.53 (market cap $39.89B), while Sirius XM Holdings Inc trades at $30.13 (market cap $10.24B). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 3.9× Sirius XM Holdings Inc's market cap, and Sirius XM Holdings Inc pays a 3.55% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | SIRI | |
|---|---|---|
Market Cap | $39.89B | $10.24B |
Sector | Health | Media |
52-Week High | $491.22 | $30.75 |
52-Week Low | $278.09 | $19.92 |
Enterprise Value | $38.15B | $19.91B |
Dividend Yield | — | 3.55% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
SIRI trades at $30.42, down 0.88% on the day, with a bullish technical signal from moving averages and neutral oscillators. The company shows solid fundamentals with a P/E of 12.89, P/B of 0.87, and consistent earnings beats in recent quarters. Recent developments include upcoming Q2 2026 results on July 30, 2026, and inclusion in the S&P MidCap 400 index.
Outlook remains positive with analyst consensus at Buy (58%) and a $31.17 price target. Key opportunities include strong cash flow and dividend yield, while risks involve competitive pressures and high debt levels. The stock offers value characteristics with upside potential near current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Sirius XM Holdings Inc
SiriusXM Holdings is now composed of two businesses: SiriusXM and Pandora. SiriusXM transmits music, talk shows, sports, and news via its two satellite radio networks, primarily to consumers in vehicles who pay a subscription fee. The firm's radios come preinstalled on a wide range of light vehicles in the U.S. and Canada. The firm acquired Pandora Media in February 2019 via an all-stock transaction. Pandora is a streaming music platform that offers an ad-supported radio option and a paid on-demand service. Liberty Media owns 80% of SiriusXM, traded through its Liberty SiriusXM Group tracking stock.
Read more on SIRI →
